Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment - a Randomized Trial
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a
high eradication rate for clarithromycin-resistant strains, and have a great potential to
replace bismuth quadruple therapy in the treatment of H. pylori infection. This study aims to
better understand the potential of both hybrid and igh-dose dual therapies in the treatment
of H. pylori infection.
.